Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
Language English Country Italy Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21811750
Knihovny.cz E-resources
- MeSH
- Amikacin pharmacology MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Cefoperazone pharmacology MeSH
- Ceftazidime pharmacology MeSH
- Ciprofloxacin pharmacology MeSH
- Gentamicins pharmacology MeSH
- Intensive Care Units * MeSH
- Penicillanic Acid analogs & derivatives pharmacology MeSH
- Microbial Sensitivity Tests MeSH
- Drug Resistance, Multiple, Bacterial MeSH
- Piperacillin pharmacology MeSH
- Pseudomonas aeruginosa drug effects MeSH
- Sulbactam pharmacology MeSH
- Tazobactam MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Amikacin MeSH
- Anti-Bacterial Agents MeSH
- Cefoperazone MeSH
- Ceftazidime MeSH
- Ciprofloxacin MeSH
- Gentamicins MeSH
- Penicillanic Acid MeSH
- Piperacillin MeSH
- Sulbactam MeSH
- Tazobactam MeSH
Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.